Urologic Cancers News
Patients on dialysis die from cancer at twice the rate as those of the same age and sex in the general population, a study found.
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
Everolimus improved recurrence-free survival in patients with very high-risk disease but not in those with intermediate high-risk disease.
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
The number of days alive and out of the hospital within the first 90 days of surgery is greater for robot-assisted surgery, but the clinical significance of the findings unclear.
In a Dutch study, each doubling of urine albumin excretion was significantly associated with a 7% increase in overall cancer risk.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of von Hippel-Lindau disease.
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
The findings may inform surveillance strategies and improve treatment outcomes.
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
A study examined bladder cancer risk and mortality among nearly 100,000 men from Ontario, Canada, who received 5-alpha reductase inhibitors.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.